Interpharm Holdings, Inc. (IPA) Announces Introduction Of A Female Hormone Product With First Year Revenue Of $11.5 Million
10/19/2005 5:10:47 PM
HAUPPAUGE, N.Y.--(BUSINESS WIRE)--July 18, 2005--Interpharm Holdings, Inc. (AMEX: IPA) today announced that it has completed the development of a female hormone product. This product, which requires a dedicated facility and specialized handling, will be exclusively distributed by Centrix Pharmaceutical, Inc. Pursuant to a multi-year contract, Centrix has committed to purchase $11.5 million of the product during the first year. Interpharm plans to commence shipment of the product within a month.
This product marks the beginning of the execution of Interpharm's recently implemented four-year business plan. This plan will shift Interpharm's focus from commodity type products with gross margins typically in the low 20% range to significantly higher margin products.
comments powered by